Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337 (Source: Ann Oncol)
Source: Ann Oncol - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337 (Source: Acta Oncologica)
Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337 (Source: Ann Oncol)
Source: Ann Oncol - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research
Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide
This study provides real-world evidence of the cardiovascular risk of AA and ENZ that may not appear in clinical trial settings. Adjusting for age, baseline comorbidities, and SES, the likelihood of a cardiovascular event did not differ between treatment groups.PMID:38591349 | DOI:10.2340/1651-226X.2024.20337 (Source: Acta Oncologica)
Source: Acta Oncologica - April 9, 2024 Category: Cancer & Oncology Authors: Onur Baser Gabriela Samayoa Archana Dwivedi Sara AlSaleh Burhan Cigdem Erdi Kizilkaya Source Type: research
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer and Prostatic Diseases, Published online: 27 March 2024; doi:10.1038/s41391-024-00816-0Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - March 27, 2024 Category: Urology & Nephrology Authors: Daniel J. George Krishnan Ramaswamy Hongbo Yang Qing Liu Adina Zhang Alexandra Greatsinger Jasmina Ivanova Betty Thompson Birol Emir Agnes Hong Stephen J. Freedland Source Type: research
Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer
ConclusionTreatment intensification using a combination of EBRT, advanced hormonal therapies, and brachytherapy may improve patient outcomes and survival in men with high-risk prostate cancer. Shared decision-making between patients and multidisciplinary teams of radiation oncologists, urologists, and medical oncologists is essential for personalizing care in this setting and deciding which strategies make sense for individual patients. (Source: World Journal of Urology)
Source: World Journal of Urology - March 16, 2024 Category: Urology & Nephrology Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
CONCLUSIONS: The RS-DAT met BE criteria (range 80%-125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC 0-24h,ss. The LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC 0-72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC 0-24h,ss; and the percentage of simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.GOV IDENTIFIER: NCT04577833.PMID:38436924 | DOI:10.1007/s40262-023-01340-5 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Alex Yu Anasuya Hazra James Juhui Jiao Peter Hellemans Anna Mitselos Hui Tian Juan Jose Perez Ruixo Nahor Haddish-Berhane Daniele Ouellet Alberto Russu Source Type: research
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation
ConclusionsThe RS-DAT met BE criteria (range 80% –125%) versus SAC based on 90% CI of GMR for Cmax,ss and AUC0 –24h,ss. The
LS-DAT was considered BE to SAC on the basis of the niraparib component meeting the BE criteria in the primary analysis for AUC0 –72h; abiraterone meeting the BE criteria in additional paired analyses based on Cmax,ss and AUC0 –24h,ss; and the percentage of
simulated LS-DAT versus SAC BE trials meeting the BE criteria for both.ClinicalTrials.gov IdentifierNCT04577833.Graphical Abstract (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 4, 2024 Category: Drugs & Pharmacology Source Type: research
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer
Prostate Cancer and Prostatic Diseases, Published online: 22 February 2024; doi:10.1038/s41391-024-00811-5Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - February 22, 2024 Category: Urology & Nephrology Authors: Ryan E. Fecteau Bridget F. Koontz Karen E. Hoffman Susan Halabi Lauren E. Howard Monika Anand Daniel J. George Tian Zhang William R. Berry W. Robert Lee Michael R. Harrison Paul G. Corn Andrew J. Armstrong Source Type: research
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer
CONCLUSION AND RELEVANCE: This single-center, retrospective cohort study found that real-world metastatic prostate cancer patients who received AA had substantially higher incidence and severity of hypertension compared with clinical trials regardless of prednisone dose. In patients with mCRPC and mCSPC, the role of prednisone dose in hypertension incidence and severity warrants further investigation. Overall, results indicate the need for closely monitoring hypertension and optimization of anti-hypertensive therapy by multidisciplinary teams in metastatic prostate cancer patients receiving AA.PMID:38344981 | DOI:10.1177/1...
Source: The Annals of Pharmacotherapy - February 12, 2024 Category: Drugs & Pharmacology Authors: Brian Lam Jo E Rodgers Benyam Muluneh Darrian Proco Young E Whang Katherine P Morgan Source Type: research
Theranostics Revolution in Prostate Cancer: Basics, Clinical Applications, Open Issues and Future Perspectives
In the last decade, the therapeutic algorithm of metastatic castration-resistant prostate cancer (mCRPC) has been revolutionized with the advent of various therapeutic strategies that significantly improved patients' outcomes. Systemic options that have demonstrated a survival benefit in this setting include chemotherapy (e.g., docetaxel and cabazitaxel), androgen receptor-signaling inhibitors (ARSI; e.g., enzalutamide and abiraterone acetate), and Poly (ADP-ribose) polymerase (PARP) inhibitors (e.g., olaparib, rucaparib, and talazoparib), either alone or combined with an ARSi, in a selected cohort of tumors harboring HRR,...
Source: Cancer Treatment Reviews - February 10, 2024 Category: Cancer & Oncology Authors: Matteo Bauckneht, Chiara Ciccarese, Riccardo Laudicella, Claudia Mosillo, Francesca D'Amico, Annunziato Anghelone, Alessandro Strusi, Viria Beccia, Sergio Bracarda, Giuseppe Fornarini, Giampaolo Tortora, Roberto Iacovelli Tags: Hot Topic Source Type: research
Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
ConclusionsWe concur with the inclusion of standard-dose AAP in India ’s publicly financed health insurance scheme for the intensification of treatment in mHSPC as it is the only cost-effective sequence among the various novel anti-androgens when compared with the docetaxel-first treatment sequence. Furthermore, a systematic reduction in the price of enzalutamide wo uld further help to improve clinical outcomes among patients with mHSPC. (Source: Applied Health Economics and Health Policy)
Source: Applied Health Economics and Health Policy - January 10, 2024 Category: Health Management Source Type: research
Concomitant antihypertensive medication and outcome of patients with metastatic castration ‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
ConclusionThe findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy. (Source: Cancer Medicine)
Source: Cancer Medicine - January 2, 2024 Category: Cancer & Oncology Authors: Ond řej Fiala,
Petr Hošek,
Hana Korunková,
Milan Hora,
Jiří Kolář,
Ondřej Šorejs,
Ondřej Topolčan,
Jan Filipovský,
Václav Liška,
Matteo Santoni,
Sebastiano Buti,
Jindřich Fínek Tags: RESEARCH ARTICLE Source Type: research
